

Haematologica
HAEMATOL/2019/229781
Version 3

Management of adults and children undergoing CAR t-cell therapy:
best practice recommendations of the European Society for Blood and
Marrow Transplantation (EBMT) and the Joint Accreditation Committee
of ISCT and EBMT (JACIE)

Ibrahim Yakoub-Agha, Christian Chabannon, Peter Bader, Grzegorz W.
Basak, Halvard Bonig, Fabio Ciceri, Selim Corbacioglu, Rafael F.
Duarte, Hermann Einsele, Michael Hudecek, Marie José Kersten,
Ulrike Köhl, Jürgen Kuball, Stephan Mielke, Mohamad Mohty, John
Murray, Arnon Nagler, Stephen Robinson, Riccardo Saccardi, Fermin
Sanchez-Guijo, John A. Snowden, Micha Srour, Jan Styczynski, Alvaro
Urbano-Ispizua, Patrick J. Hayden, and Nicolaus Kröger

Disclosures: IYA: honoraria from Novartis, Kite/Gilead, and Celgene. He is the Principal Investigator for several clinical trials involving CAR T cell therapies. CH has received grants from Sanofi, honoraria from Sanofi, Gilead, Novartis, Bellicum and Terumo BCT, and funding for equipment to his institution from Miltenyi and Fresenius. PB: Research Grants: Neovii, Riemsler, Medac; Advisory Board: Novartis, Cellgene, Amgen, Medac, Servier (Institut); Medac: Patent and Royalties GWB: honoraria from Novartis and Gilead. HB: honoraria from Novartis and Celgene and served on the advisory board of Novartis. FC declares no conflict of interest SC declares no conflict of interest RFD: honoraria from Gilead and Celgene. HE: honoraria from Celgene, Takeda, Janssen, and BMS. MH: member of the speaker's bureau of Celgene and Gilead. Michael Hudecek is inventor on patent applications related to CAR-T technologies that have been filed by the Fred Hutchinson Cancer Research center (Seattle, WA) and the University of Würzburg (Würzburg, Germany). MJK is an investigator for several clinical trials involving CAR T cell therapies and has received honoraria from Novartis, Kite/Gilead and Celgene. UK: honoraria from Novartis, Astra Zeneca and Miltenyi. JK is inventor on different patents with T cell receptor sequences, recognition mechanisms, and isolation strategies of TEG and CAR T, scientific advisor and shareholder of Gadeta and received research funding from Miltenyi Biotech, Novartis, and Gadeta. SM received honoraria from, Celgene, Miltenyi, Kiadis, Bellicum, Jazz Pharmaceuticals and Novartis. MM declares lecture honoraria and consultant- Novartis, Amgen and Pfizer JM declares no conflict of interest AN declares no conflict of interest SR: Gilead and Novartis Advisory Board and speaker fees RS declares no conflict of interest FSG declares no conflict of interest JAS declares speaker fees from Janssen, Jazz and Gilead and IDMC membership from Kiadis Pharma. He is the Chair of NHS England Specialised Commissioning Clinical Reference Group for BMT MS declares no conflict of interest JS: honoraria from Novartis and Gilead AUI: Travel grant from Gilead and advisory boards with Celgene and Gilead PJH: honoraria from Amgen and Alnylan, Travel support from Takeda NK: honoraria from Novartis and Celgene

Contributions: IYA, PH, HB, AN, RS, FSG, JS and AJS designed the research and wrote the methodology chapter and the first draft; NK, PH and IYA wrote the introduction; PH, RFD and GBW wrote the patients eligibility chapter; PH and ST wrote the blood tests and imaging chapter; CC and HB wrote the chapters on apheresis readiness, apheresis, product receiving, storage, transportation and thawing; FC and HE wrote the bridging therapy chapter; AN and MM wrote the chapter on lymphodepletion conditioning, IYA, PH, JM and SC wrote the short-term complications chapter; JS, JM, PH and IYA wrote the chapter on medium-term complications; MJK wrote the chapter on antiinfective prophylaxis; JK, FSG and JAS wrote the chapters related to long-term follow-up and JACIE and regulatory issues. All authors proofed and approved the final manuscript.